Plain-language summary

This Phase 2 trial is testing Selinexor and anti-PD-1 antibody plus Golidocitinib for people whose NK/T-cell lymphoma has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 14 Years to 75 Years years
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Selinexor, anti-PD-1 antibody plus Golidocitinib (DRUG): Selinexor, 40mg, qw, po; anti-PD1 antibody, 200mg, d1, i.v. (21d cycle); Golidocitinib, Dose 1, 150mg, qod, po; Dose2, 150mg, qd, po.

Drugs / treatments

Selinexor, anti-PD-1 antibody plus Golidocitinib

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details